For years, the obesity drug conversation has been a single-track debate: which incretin is strongest?

Semaglutide versus tirzepatide. Dual agonist versus triple agonist. GLP-1 versus GLP-1 + GIP versus GLP-1 + GIP + glucagon.

Eloralintide changes the question entirely.

It doesn't compete with GLP-1s. It activates a completely different receptor system — and in Phase 2 trials published in The Lancet, it produced up to 20.1% average body weight reduction at 48 weeks at the highest dose, without touching a single incretin receptor.

Important upfront: Eloralintide is an investigational compound. It has not been approved by the FDA or any other regulatory agency. Phase 3 clinical trials are currently underway. It is not commercially available.

Here's everything the research actually shows.

What Eloralintide Is

Generic name: Eloralintide Developer: Eli Lilly and Company Former designation: LY3841136 Class: Selective amylin receptor agonist Administration: Once-weekly subcutaneous injection Status: Phase 2 complete (The Lancet, 2025). Phase 3 underway — monotherapy studies initiated by end of 2025 (Lilly press release, November 6, 2025); Phase 3 add-on study (in participants on weekly incretin therapy) first submitted January 30, 2026.

Eloralintide is an analog of amylin — a hormone naturally co-secreted with insulin by pancreatic beta cells. It was engineered to:

Activate the human amylin 1 receptor (AMY1R) with 12x greater potency than the calcitonin receptor
Achieve once-weekly dosing via conjugation to a C20 fatty diacid for reversible albumin binding
Minimize immunogenicity risk and self-aggregation — two problems that limited earlier amylin analogs
Maintain high selectivity for the amylin receptor vs. the calcitonin receptor

Primary publication: The Lancet — "Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial" (PIIS0140673625021555)

Discovery-to-proof-of-concept paper: Briere DA, Qu H, Lansu K, et al. "Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept." Molecular Metabolism. 2025;102:102271. PMC12640043

How the Amylin System Works — And Why It's Different

To understand why eloralintide matters, you need to understand what amylin does and why it's distinct from the incretin system.

Amylin is not a gut hormone. It's a pancreatic peptide — co-secreted with insulin from beta cells in response to meals. It acts centrally (primarily in the area postrema and hypothalamus) to:

Signal satiety and promote fullness during and after meals
Reduce meal size by limiting meal duration
Slow gastric emptying (through different pathways than GLP-1)
Suppress prandial glucagon release
Reduce prandial glucose excursions

The distinction from GLP-1: GLP-1 primarily signals through gut-brain axis pathways, reducing appetite and food noise. Amylin primarily signals meal-time satiety — the feeling of having had enough during a meal. These are complementary mechanisms operating through different receptors with different downstream effects.

The pramlintide precedent: The first FDA-approved amylin receptor agonist — pramlintide (Symlin, approved 2005) — demonstrated meaningful effects on satiety and weight as an adjunct to insulin therapy. It required three-times-daily injections and was limited by tolerability. Eloralintide is the long-acting, once-weekly engineered successor.

The Phase 2 Data — From Primary Sources

Trial: NCT06230523 — Phase 2, 48-week, multicentre, double-blind, randomised, placebo-controlled Population: 263 adults with obesity or overweight, at least one obesity-related comorbidity, without type 2 diabetes Average baseline weight: 109.1 kg (240.5 lbs) Published: The Lancet (PIIS0140673625021555) Lilly press release: lilly.gcs-web.com, 2025

Primary endpoint — mean percent change in body weight at 48 weeks (efficacy estimand):

| Dose | Weight Change | Weight Lost | vs. Placebo | |---|---|---|---| | Placebo | -0.4% | -1.0 lb | — | | Eloralintide 1 mg | -9.5% | -22.5 lbs | Superior | | Eloralintide 3 mg | -12.4% | -29.3 lbs | Superior | | Eloralintide 6 mg | -17.6% | -41.2 lbs | Superior | | Eloralintide 9 mg | -20.1% | -47.0 lbs | Superior | | Eloralintide 6/9 mg (escalation) | -19.9% | -46.3 lbs | Superior | | Eloralintide 3/6/9 mg (escalation) | -16.4% | -39.2 lbs | Superior |

All treatment arms met the primary endpoint with superior weight reductions compared to placebo.

Secondary endpoints: All doses delivered clinically meaningful improvements in waist circumference, blood pressure, lipid profiles, glycemic control, and inflammatory markers (hsCRP).

Tolerability — honest assessment: Eloralintide is not a nausea-free drug. The most commonly reported adverse events across studies include nausea and fatigue, which were generally described as mild to moderate. The Lancet publication reports nausea as the most common adverse event across doses. At the 6 mg fixed-dose arm, nausea was reported in approximately 64% of participants — a clinically meaningful rate. The full adverse event tables, including discontinuation rates and severity breakdowns, are in the published Lancet paper and should be reviewed in full.

Important note on cross-trial comparisons: The Phase 2 data above is not directly comparable to Phase 3 data from semaglutide, tirzepatide, or other agents. These are different trials, different populations, different durations, and different study designs. No head-to-head data exists. Cross-trial efficacy comparisons should be interpreted with significant caution.

The Combination Story — Eloralintide + Tirzepatide

Lilly is also evaluating eloralintide as an add-on to existing incretin therapy. Two relevant datasets:

Phase 1b human combination study — presented at EASD 2026. Trial registrations: NCT06345066 and NCT06297616. Design: investigator- and participant-blinded, placebo-controlled, multiple-ascending-dose proof-of-concept studies in adults with obesity/overweight without T2D. Safety, tolerability, pharmacokinetics, and pharmacodynamics were the primary endpoints. Full efficacy results from this study have not been published at time of writing.

Preclinical combination data — presented at ADA 2026 in diet-induced obese rats. Co-administration of tirzepatide and eloralintide produced additive effects on body weight and fat mass reduction compared to either compound alone. Preclinical results do not reliably predict human outcomes.

Ongoing Phase 2 combination study: NCT06603571 — evaluating eloralintide alone or with tirzepatide in adults with obesity/overweight and type 2 diabetes.

The mechanistic rationale: Tirzepatide activates GLP-1 and GIP receptors. Eloralintide activates the amylin receptor. These are independent satiety systems with different receptors and different downstream pathways — which is why combination effects are scientifically plausible rather than redundant.

The Amylin Class Landscape

Eloralintide sits within a broader amylin receptor development wave:

Cagrilintide (Novo Nordisk): Long-acting amylin analog. In Phase 3 in combination with semaglutide as CagriSema. REDEFINE Phase 3 data: approximately 22.7% weight loss at 68 weeks (ADA 2026; primary source: Novo Nordisk press release). NDA filed 2026. Most advanced amylin program.

Petrelintide (Zealand/Roche): Phase 3 announced. Phase 1 safety/tolerability/PK data published 2026 in Diabetes, Obesity and Metabolism.

Amycretin (Novo Nordisk): First-in-class GLP-1/amylin dual receptor co-agonist. Phase 1b/2a subcutaneous data: approximately 24.3% weight loss at 36 weeks (Novo Nordisk; not independently verified in peer-reviewed publication at time of writing). Phase 2 ongoing.

Pramlintide (Symlin): FDA-approved 2005 as insulin adjunct for T1D and T2D. The proof-of-concept that amylin biology produces meaningful clinical effects in humans.

The pattern: multiple major pharmaceutical companies are simultaneously investing in amylin receptor biology, converging on the hypothesis that amylin + incretin produces superior outcomes to incretin alone.

Access and Regulatory Status

Eloralintide is an investigational compound. It is not FDA-approved, EMA-approved, or approved by any regulatory agency. It has not been submitted for regulatory review under any pathway.

It is not commercially available. Eloralintide is being studied exclusively within Lilly's clinical trial network. There is no legitimate commercial, compounding, or research-use-only source for eloralintide outside approved clinical trial protocols. Any material sold under this name outside a clinical trial context should be presumed counterfeit or mislabeled.

It was not among the seven PCAC compounds reviewed at the July 23-24, 2026 advisory committee meeting. The PCAC process reviewed BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and Emideltide — not eloralintide.

Realistic regulatory timeline for approval: Eloralintide has a 37-amino-acid main chain — below FDA's 40-amino-acid threshold (21 CFR 600.3(h)(6)) that distinguishes biologics from drugs. Peptides at or below that length are regulated as drugs under the NDA pathway, the same route taken by semaglutide (31 aa, NDA 209637), tirzepatide (39 aa), and pramlintide (37 aa). If Phase 3 data is available in 2027-2028, an NDA filing could follow in 2028-2029. FDA approval, if granted, would be 2029-2030 at earliest.

The Bottom Line

Eloralintide is one of the most scientifically interesting obesity compounds in development because it doesn't repeat what already exists — it adds a genuinely independent mechanism.

A selective amylin receptor agonist that produced 20.1% weight loss at 48 weeks at the highest dose as a standalone monotherapy, from a system that complements rather than competes with the entire existing GLP-1 class.

The combination potential with existing incretin therapies may ultimately prove to be the more significant long-term clinical story. Phase 3 is underway. Combination Phase 2 data is pending.

We'll track every data release as it comes.

→ Follow the latest at PeptidesGPT.com/research

Sources:

The Lancet: "Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial" — PIIS0140673625021555
Eli Lilly press release: "Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study" — lilly.gcs-web.com (2025)
Eli Lilly press release: Phase 3 monotherapy initiation — November 6, 2025
Briere DA, Qu H, Lansu K, et al. "Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept." Molecular Metabolism. 2025;102:102271. PMC12640043
Eli Lilly / ADA 2026 Poster #3082-LB: "The Selective Amylin Analog, Eloralintide, Enhanced Weight-Loss Efficacy When Combined With Tirzepatide in Diet-Induced Obese Rats"
EASD 2026 Abstract: "Safety, tolerability, pharmacokinetics and pharmacodynamics of eloralintide and tirzepatide co-administered as once-weekly subcutaneous injections" — Eli Lilly (NCT06345066, NCT06297616)
ClinicalTrials.gov: NCT06230523 (Phase 2 monotherapy), NCT06345066 and NCT06297616 (Phase 1b combination safety/PK), NCT06603571 (Phase 2 combination with tirzepatide)
Novo Nordisk press release: CagriSema REDEFINE Phase 3 data, ADA 2026
Diabetes, Obesity and Metabolism: Petrelintide Phase 1 safety/tolerability/PK data (2026)

PeptidesGPT is an educational platform. Eloralintide is an investigational compound that has not been approved by the FDA or any other regulatory agency. This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before making decisions about your health or protocol.